Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleArticle

Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease

Tomoyuki Fujisawa, Hironao Hozumi, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui and Takafumi Suda
The Journal of Rheumatology May 2019, jrheum.180825; DOI: https://doi.org/10.3899/jrheum.180825
Tomoyuki Fujisawa
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tomoyuki Fujisawa
Hironao Hozumi
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hironao Hozumi
Hideki Yasui
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuzo Suzuki
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masato Karayama
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuki Furuhashi
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noriyuki Enomoto
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yutaro Nakamura
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoki Inui
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takafumi Suda
From the Second Division, Department of Internal Medicine, and the Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. T. Fujisawa, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Hozumi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; H. Yasui, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Suzuki, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; M. Karayama, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; K. Furuhashi, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Enomoto, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; Y. Nakamura, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine; N. Inui, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine; T. Suda, MD, PhD, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine. Address correspondence to Dr. T. Fujisawa, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan. E-mail: fujisawa@hama-med.ac.jp. Accepted for publication November 15, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • References
  • Info & Metrics
  • PDF
  • eLetters
Next
Loading

Article Figures & Data

Additional Files

  • Data Supplement

    • 180825DataSuppl.pdf
Next
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 12
1 Dec 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
Citation Tools
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease
Tomoyuki Fujisawa, Hironao Hozumi, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui, Takafumi Suda
The Journal of Rheumatology May 2019, jrheum.180825; DOI: 10.3899/jrheum.180825

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease
Tomoyuki Fujisawa, Hironao Hozumi, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Yutaro Nakamura, Naoki Inui, Takafumi Suda
The Journal of Rheumatology May 2019, jrheum.180825; DOI: 10.3899/jrheum.180825
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis
  • Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care
  • Changes in the Presentation of Incident Gout and the Risk of Subsequent Flares: A Population-based Study over 20 Years
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • AV Rheum

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire